Design, synthesis, and preliminary evaluation of substituted cinnamic acid esters as selective matrix metalloproteinase inhibitors

Drug Development Research

Volumn 73, Issue 6, 2012, Pages 317-324

  Shi, Zhi Hao ^a,b   Li, Nian Guang ^b   Shi, Qian Ping ^b   Hao Tang, ^b   Tang, Yu Ping ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

activity relationship; caffeic acid; matrix metalloproteinases; structure; tumor

Indexed keywords

BENZENE; CAFFEIC ACID; CINNAMIC ACID DERIVATIVE; CYCLOHEXYL 3 (3,4 DIHYDROXYPHENYL)ACRYLATE; CYCLOHEXYL 3 (4 HYDROXY 3 METHOXYPHENYL)ACRYLATE; CYCLOHEXYL CINNAMATE; CYCLOPENTYL 3 (3,4 DIHYDROXYPHENYL)ACRYLATE; CYCLOPENTYL CINNAMATE; GELATINASE A; GELATINASE B; HYDROXYL RADICAL; INTERSTITIAL COLLAGENASE; ISOBUTYL 3 (3,4 DIHYDROXYPHENYL)ACRYLATE; ISOBUTYL CINNAMATE; ISOPENTYL 3 (3,4 DIHYDROXYPHENYL)ACRYLATE; ISOPENTYL CINNAMATE; ISOPROPYL 3 (3,4 DIHYDROXYPHENYL)ACRYLATE; ISOPROPYL CINNAMATE; MATRIX METALLOPROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ESTERIFICATION; IC 50; MICROWAVE RADIATION; MOLECULAR DOCKING; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 84866388387     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21015     Document Type: Article

References (33)

1. Aimes RT, Quigley JP,. 1995. Matrix metalloproteinase-2 is an interstitial collagenase: inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 270: 5872-5876.
2. Baragi VM, Shaw BJ, Renkiewicz RR, Kuipers PJ, Welgus HG, Mathrubutham M, Cohen JR, Rao SK,. 2000. A versatile assay for gelatinases using succinylated gelatin. Matrix Biol 19: 267-273. (Pubitemid 30601759)
3. de Campos Buzzi F, Franzoi CL, Antonini G, Fracasso M, Cechinel Filho V, Yunes RA, Niero R,. 2009. Antinociceptive properties of caffeic acid derivatives in mice. Eur J Med Chem 44: 4596-4602.
4. Chung TW, Moon SK, Chang YC, Ko JH, Lee YC, Cho G, Kim SH, Kim JG, Kim CH,. 2004. Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism. FASEB J 18: 1670-1681. (Pubitemid 39463706)
5. Crabbe T, O'Connel JP, Smith BJ, Docherty AJP,. 1994. Reciprocated matrix metalloproteinase activation: a process performed by interstitial collagenase and progelatinase A. Biochemistry 33: 14419-14425.
6. Dahlberg L, Billinghurst RC, Manner P, Nelson F, Webb G, Ionescu M, Reiner A, Tanzer M, Zukor D, Chen J, et al. 2000. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum 43: 673-682. (Pubitemid 30394960)
7. Gooley PR, O'Connell JF, Marcy AI, Cuca GC, Salowe SP, Bush BL, Hermes JD, Esser CK, Hagmann WK, Springer JP, et al. 1994. The NMR structure of the inhibited catalytic domain of human stromelysin-1. Nat Struct Biol 1: 111-118. (Pubitemid 24974824)
8. Hodgson J,. 1995. Remodeling MMPIs. Biotechnology 13: 554-557.
9. Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, et al. 1999. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99: 81-92. (Pubitemid 29468632)
10. Hutchinson JW, Tierney GM, Parsons SL, Davis TRC,. 1998. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg Br 80-B: 907-908. (Pubitemid 28457089)
11. Kappe CO,. 2004. Controlled microwave heating in modern organic synthesis. Angew Chem Int Ed Engl 43: 6250-6284. (Pubitemid 40036603)
12. Li NG, Shi ZH, Tang YP, Duan JA,. 2009a. Selective matrix metalloproteinase inhibitors for cancer. Curr Med Chem 16: 3805-3827.
13. Li NG, Shi ZH, Tang YP, Li BQ, Duan JA,. 2009b. Highly efficient esterification of ferulic acid under microwave irradiation. Molecules 14: 2118-2126.
14. Li YQ,. 1999. Catalytic esterifications of carboxylic acids and alcohols by sodium bisulfate monohydrate. Synth Commun 29: 3901-3903.
15. Lovejoy B, Cleasby A, Hassell AM, Longley K, Luther MA, Weigl D, McGeehan G, McElroy AB, Drewry D, Lanbert MH, et al. 1994. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science 263: 375-377.
16. MacDougall JR, Matrisian LM,. 1995. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 14: 351-362. (Pubitemid 26030973)
17. Maki BE, Chan A, Phillips EM, Scheidt KA,. 2009. N-heterocyclic carbene-catalyzed oxidations. Tetrahedron 65: 3102-3109.
18. Murakami A, Kadota M, Takahashi D, Taniguchi H, Nomura E, Hosoda A, Tsuno T, Maruta Y, Ohigashi H, Oshimizu K,. 2000. Suppressive effects of novel ferulic acid derivatives on cellular responses induced by phorbol ester, and by combined lipopolysaccharide and interferon-γ. Cancer Lett 157: 77-85. (Pubitemid 30421234)
19. Nagaoka T, Banskota AH, Tezuka Y, Saiki I, Kadota S,. 2002. Selective antiproliferative activity of caffeic acid phenethyl ester analogues on highly liver-metastatic murine colon 26-L5 carcinoma cell line. Bioorg Med Chem 10: 3351-3359. (Pubitemid 34863215)
20. Nagase H, Woessner JF Jr,. 1999. Matrix metalloproteinases. J Biol Chem 274: 21491-21494.
21. Narasimhana B, Belsareb D, Pharandeb D, Mouryac V, Dhake A,. 2004. Esters, amides and substituted derivatives of cinnamic acid: synthesis, antimicrobial activity and QSAR investigations. Eur J Med Chem 39: 827-834. (Pubitemid 39302632)
22. 2, a superacidic perfluorinated resinsulfonic acid catalyst. Synthesis 12: 929-930.
23. Overall CM, Lõpez-Otín C,. 2002. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657-672. (Pubitemid 37328917)
24. Park WH, Kim SH, Kim CH,. 2005. A new matrix metalloproteinase-9 inhibitor 3,4-dihydroxycinnamic acid (caffeic acid) from methanol extract of Euonymus alatus: isolation and structure determination. Toxicology 207: 383-390.
25. Ray JM, Stetler-Stevenson WG,. 1996. Matrix metalloproteinases and malignant disease: recent developments. Exp Opin Invest Drugs 5: 323-335. (Pubitemid 26096491)
26. Scatena R,. 2000. Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases. Exp Opin Invest Drugs 9: 2159-2165.
27. Sova M, Perdih A, Kotnik M, Kristan K, Lanišnik Rižner T, Solmajer T, Gobec S,. 2006. Flavonoids and cinnamic acid esters as inhibitors of fungal 17β-hydroxysteroid dehydrogenase: a synthesis, QSAR and modelling study. Bioorg Med Chem 14: 7404-7418. (Pubitemid 44486808)
28. Stetler-Stevenson WG,. 1999. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103: 1237-1241. (Pubitemid 29218293)
29. Steward WP,. 1999. Marimastat (BB2516): current status of development. Cancer Chemother Pharmacol 43: S56-S60. (Pubitemid 29244634)
30. 2-catalyzed oxidative coupling reaction of benzenes with olefins in the presence of molybdovanadophosphoric acid under atmospheric dioxygen and air. J Org Chem 69: 1221-1226. (Pubitemid 38233404)
31. Uwai K, Osanai Y, Imaizumi T, Kanno S, Takeshita M, Ishikaw M,. 2008. Inhibitory effect of the alkyl side chain of caffeic acid analogues on lipopolysaccharide-induced nitric oxide production in RAW264.7 macrophages. Bioorg Med Chem 16: 7795-7803.
32. Verma RP, Hansch C,. 2007. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem 15: 2223-2268. (Pubitemid 46240907)
33. 2O in synthesis: a convenient and efficient catalyst for the esterification of aromatic carboxylic acids with alcohols. Synth Commun 29: 607-611.